Cite
HARVARD Citation
Concin, N. et al. (n.d.). 2022-RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies. International journal of gynecological cancer. p. A185. [Online].